TLL-2 (Recombinant)

Recombinant Protein · expressed in HEK293
Citation tracking pending
Recombinant human Tolloid-like protein 2 (TLL-2, Q9Y6L7), expressed in HEK293 cells. Secreted metalloprotease active against pro-lysyl oxidase; used in cleavage assays, inhibitor screens, and antibody validation studies.
Expression system
HEK293
Cat. #
REC-TLL2

In stock

SKU
REC-TLL2
$498.00

Target Overview

TLL-2 (Tolloid-like protein 2; UniProt Q9Y6L7) is a secreted astacin-family zinc metalloprotease encoded by the TLL2 gene on human chromosome 10. The full-length human sequence spans 1,015 amino acids and includes a prodomain, an astacin catalytic domain, and multiple CUB and EGF-like domains characteristic of the BMP-1/Tolloid subfamily. The mature protease is glycosylated and secreted into the extracellular matrix, where it acts on a defined set of substrates in the pericellular environment. This recombinant is produced in HEK293 cells, providing mammalian post-translational processing — including N-linked glycosylation and disulfide bond formation — that is critical for correct folding and proteolytic activity of multi-domain extracellular metalloproteases. HEK293-derived TLL-2 is therefore the preferred format for substrate cleavage assays, kinetic characterisation, and inhibitor IC50 determinations requiring a physiologically relevant enzyme form. The primary characterised substrate of TLL-2 is pro-lysyl oxidase (pro-LOX), the precursor to the copper-dependent amine oxidase responsible for cross-linking collagen and elastin in the extracellular matrix. Cleavage of the pro-LOX propeptide by TLL-2 is required for LOX activation. In addition, TLL-2 participates in dorsal-ventral axis patterning during embryonic development, functioning in the BMP signalling pathway by processing Chordin and related BMP antagonists. Researchers using this recombinant for antibody validation — for example, as a positive-control antigen on Western blot or in IHC blocking experiments — can pair it with the matched Triple Point Biologics TLL-2 antibody (SKU: RP-TLL2), which has been validated for Western blot against human TLL-2.

Background

TLL-2 belongs to the BMP-1/Tolloid-like subfamily of astacin metalloproteases, a group of secreted zinc-dependent endopeptidases that regulate extracellular matrix assembly and BMP (bone morphogenetic protein) signalling gradients. The founding member, Drosophila Tolloid, was identified as a modifier of the decapentaplegic pathway; vertebrate paralogues including BMP-1, mTLD, TLL-1, and TLL-2 have since been characterised as key regulators of ECM maturation and developmental morphogenesis. The most precisely defined biochemical role of TLL-2 is proteolytic activation of pro-lysyl oxidase (pro-LOX). LOX and its paralogues (LOXL1–4) cross-link lysine and hydroxylysine residues in collagen and elastin, providing tensile strength to connective tissues. Cleavage of the ~18 kDa pro-LOX propeptide is required for enzymatic activation, and TLL-2 has been established as the predominant protease executing this step in specific tissue contexts. This positions TLL-2 as a proximal upstream regulator of collagen network stiffness, a property studied extensively in fibrosis, cartilage biology, and vascular wall mechanics. TLL-2 also processes Chordin, an antagonist of BMP-2 and BMP-4. By cleaving Chordin, TLL-2 liberates active BMPs to signal through their cognate receptors, contributing to dorsal-ventral patterning during embryogenesis and to skeletogenesis postnatally. Mice deficient in TLL-2 display skeletal abnormalities, linking its proteolytic activity to bone development programs investigated in musculoskeletal research. In broader genomic and transcriptomic contexts, TLL-2 has appeared as a nominated locus in studies investigating metabolic and cardiovascular phenotypes. A genome-wide association study in African-ancestry cohorts (Bentley AR et al., 2021, Hum Mol Genet, PMID 34196372) identified TLL-2 among loci with associations to lipid traits, consistent with emerging interest in ECM remodelling enzymes as research targets in cardiometabolic biology. TLL-2 has also been nominated in transcriptomic analyses of weight-loss response variation and in exome studies of pulmonary disease, though the mechanistic basis of these associations remains under active investigation. For in-vitro research, recombinant TLL-2 is used to reconstitute pro-LOX processing in defined systems, to characterise synthetic or endogenous inhibitors of the astacin catalytic domain, and to validate antibodies raised against TLL-2 or its cleavage products. Triple Point Biologics has produced proteinase and inhibitor research reagents since 1994; this recombinant is manufactured to a research-grade standard consistent with that history.

Applications

  • Pro-lysyl oxidase (pro-LOX) cleavage assay to confirm TLL-2 proteolytic activity by SDS-PAGE or immunoblot detection of the released propeptide
  • Inhibitor IC50 determination using fluorogenic astacin substrate peptides in a continuous kinetic format
  • Chordin processing assay to assess TLL-2 activity in reconstituted BMP signalling studies
  • Positive-control antigen for Western blot calibration when paired with the matched Triple Point Biologics TLL-2 antibody (SKU: RP-TLL2)
  • IHC blocking antigen to confirm antibody specificity in tissue sections using recombinant protein pre-absorption
  • Surface plasmon resonance (SPR) or BLI binding assays to determine affinity constants of candidate TLL-2 inhibitors or binding partners
  • Substrate identification by mass spectrometry — incubating recombinant TLL-2 with complex ECM preparations to catalogue cleavage sites
  • Collagen cross-linking pathway reconstitution experiments examining the TLL-2 → activated LOX → collagen fibril axis in cell-free systems

References

  1. Bentley AR et al. GWAS in Africans identifies novel lipids loci and demonstrates heterogenous association within Africa. Hum Mol Genet. 2021. doi:10.1093/hmg/ddab174. PMID: 34196372.
  2. Vela-Vásquez DA et al. Transcriptomic analysis in peripheral blood mononuclear cells from hyper and hypo weight-loss responders. Genes Nutr. 2025. doi:10.1186/s12263-025-00783-8. PMID: 41087885.
  3. Su L et al. Exome and Sputum Microbiota as Predictive Markers of Frequent Exacerbations in Chronic Obstructive Pulmonary Disease. Biomolecules. 2022. doi:10.3390/biom12101481. PMID: 36291689.
  4. Huang K et al. Endothelial NOX1 Drives Obesity via Skeletal Muscle Mitochondrial Dysfunction. Circ Res. 2026. doi:10.1161/CIRCRESAHA.125.326768. PMID: 42021739.

Additional Specifications

Storage Buffer 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol
Endotoxin Level <0.1 EU/µg by LAL
Purity (%) >90% by SDS-PAGE
Expression System HEK293
Subcellular Localization Subcellular localization not yet annotated

Frequently Asked Questions

What molecular weight does recombinant TLL-2 run at on SDS-PAGE and Western blot?

The full-length human TLL-2 sequence (Q9Y6L7) is 1,015 amino acids, giving a predicted unmodified MW of ~114 kDa. Because this recombinant is expressed in HEK293 cells, N-linked glycosylation adds appreciable mass: expect a diffuse band in the range of 120–135 kDa under reducing SDS-PAGE conditions. The smearing is characteristic of heterogeneous glycosylation and is not a purity artefact — >90% purity by SDS-PAGE is confirmed by Coomassie. PNGase F treatment will collapse the band toward the predicted backbone mass if a sharper signal is needed.

Is recombinant TLL-2 the full-length protein or just the catalytic domain, and is the prodomain removed?

This recombinant represents the secreted, processed form of TLL-2. The N-terminal prodomain undergoes autocatalytic or trans removal during HEK293 secretion, consistent with the maturation mechanism described for other BMP-1/Tolloid family members. The active enzyme retains the astacin catalytic domain together with the downstream CUB and EGF-like domains, which are required for substrate recognition and binding. If your experiment requires the zymogen or a defined prodomain-intact construct, this format is not appropriate — contact us to discuss custom expression options.

What substrates does TLL-2 cleave and how do I set up a substrate cleavage activity assay?

TLL-2's best-characterised substrates are the BMP antagonist Chordin and the small leucine-rich proteoglycan Biglycan; cleavage of Chordin at specific sites potentiates BMP signalling. For a direct cleavage assay, incubate recombinant TLL-2 (50–200 nM) with recombinant Chordin (500 nM–1 µM) in assay buffer — 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM CaCl2 — at 37 °C for 1–4 hours, then resolve by SDS-PAGE and detect cleavage fragments. The calcium is essential; chelating agents (EDTA, EGTA) will abolish activity. Include a no-enzyme control and a heat-inactivated TLL-2 control in every experiment.

What buffer should I use for TLL-2 activity assays and what conditions inhibit the enzyme?

The storage buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol, 5 mM CaCl2) is compatible with direct use in most activity assays; simply dilute into the same buffer base without glycerol for kinetic runs where viscosity is a concern. CaCl2 at 1–5 mM is required for catalytic activity — do not use EDTA- or EGTA-containing buffers. Broad-spectrum metalloprotease inhibitors such as 1,10-phenanthroline (1 mM) or marimastat (10 µM) serve as appropriate positive inhibitor controls. Zinc chelation (e.g., TPEN) at low micromolar concentrations also abolishes activity and can be used to confirm zinc-dependence of any observed cleavage.

What starting enzyme concentration should I use for TLL-2 IC50 inhibitor screening assays?

For IC50 determinations, begin with recombinant TLL-2 at 50–100 nM in assay buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM CaCl2, pH 7.5, 37 °C). This concentration sits within the linear range of activity for substrate cleavage readouts at the 1–4 hour timepoint and provides adequate signal-to-noise without substrate depletion at typical substrate concentrations (500 nM–1 µM Chordin). Pre-incubate enzyme with inhibitor for 30 minutes before substrate addition to allow equilibration. Verify that DMSO vehicle (used for most small-molecule inhibitors) is ≤0.5% v/v, as higher concentrations measurably reduce TLL-2 activity.

Can I use recombinant TLL-2 as a positive control for Western blot with the RP-TLL2 antibody?

Yes — REC-TLL2 is the recommended positive control for the matched rabbit polyclonal antibody RP-TLL2 (/anti-tll-2-rabbit-polyclonal-antibody). Load 25–100 ng of recombinant TLL-2 per lane under reducing conditions; the antibody detects the glycosylated HEK293-expressed protein as a diffuse band at 120–135 kDa. This combination is particularly useful when validating RP-TLL2 on novel cell lysates or tissue sections, since the recombinant provides a defined, quantified reference band at the correct apparent MW. Both products are produced from the same lab platform, so epitope and species compatibility are confirmed.

How much recombinant TLL-2 should I load as a positive control for Western blot, and what antibody dilution pairs with it?

Load 50 ng of REC-TLL2 per lane as a starting point alongside your experimental samples. At this amount, RP-TLL2 used at 1:500–1:2,000 (primary, overnight 4 °C) with a standard HRP-conjugated anti-rabbit secondary at 1:5,000–1:10,000 gives a clear band at 120–135 kDa with minimal background on PVDF or nitrocellulose. If your cell lysate lane shows a faint signal, increase load to 100 ng; this titration ensures you are in the linear detection range. Total protein loaded per lysate lane should be 20–40 µg for a detectable endogenous TLL-2 band in expressing cell lines.

How should I store and handle recombinant TLL-2 to maintain activity, and what is its shelf life?

REC-TLL2 is supplied in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol, 5 mM CaCl2 as single-use aliquots. Store at -20 °C immediately upon receipt. Avoid repeated freeze-thaw cycles — each cycle measurably reduces metalloprotease activity due to aggregation and zinc loss. Working aliquots can be held at 4 °C for up to 48 hours; do not leave at room temperature. When diluting for assays, use the same buffer base to prevent dilution shock. Under recommended storage conditions, activity is stable for at least 12 months from the date of manufacture shown on the CoA.

Validation imagery coming soon

Western blot validation figures for REC-TLL2 will be published here as they are produced in-house.

If you would like to see existing validation data for this antibody before publication, request a sample copy.

  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →